Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity

Journal of Medicinal Chemistry

Volumn 50, Issue 12, 2007, Pages 2767-2778

  Kasibhatla, Srinivas R ^a   Hong, Kevin ^a   Biamonte, Marco A ^a   Busch, David J ^a   Karjian, Patricia L ^a   Sensintaffar, John L ^a   Kamal, Adeela ^a   Lough, Rachel E ^a   Brekken, John ^a   Lundgren, Karen ^a   Grecko, Roy ^a   Timony, Gregg A ^a   Ran, Yingqing ^a   Mansfield, Robert ^a   Fritz, Lawrence C ^b   Ulm, Edgar ^a   Burrows, Francis J ^a   Boehm, Marcus F ^a  

^a BIOGEN   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 2 (2 AMINO 6 CHLOROPURIN 9 YLMETHYL) 3,5 DIMETHYLPYRIDIN 4 OL; 2 AMINO 9 (2 CHLORO 3,4,5 TRIMETHOXYBENZYL) 9H PURIN 6 OL; 6 BROMO 9 (2 BROMO 3,4,5 TRIMETHOXYBENZYL) 9H PURIN 2 YLAMINE; 6 CHLORO 9 (2 BROMO 3,4,5 TRIMETHOXYBENZYL) 9H PURIN 2 YLAMINE; 6 CHLORO 9 (2 CHLORO 3,4,5 TRIMETHOXYBENZYL) 9H PURIN 2 YLAMINE; 6 CHLORO 9 (2 IODO 3,4,5 TRIMETHOXYBENZYL) 9H PURIN 2 YLAMINE; 6 CHLORO 9 (2,5 DIMETHOXYBENZYL) 9H PURIN 2 YLAMINE; 6 CHLORO 9 (3,4,5 TRIMETHOXYBENZYL) 9H PURIN 2 YLAMINE; 6 CHLORO 9 (3,4,5 TRIMETHYLPYRIDIN 2 YLMETHYL) 9H PURIN 2 YLAMINE; 6 CHLORO 9 (3,5 DIMETHYL 4 AMINOPYRIDIN 2 YLMETHYL) 9H PURIN 2 YLAMINE; 6 CHLORO 9 (3,5 DIMETHYL 4 CYANOPYRIDIN 2 YLMETHYL) 9H PURIN 2 YLAMINE; 6 CHLORO 9 (3,5 DIMETHYL 4 METHYLSULFANYLPYRIDIN 2 YLMETHYL) 9H PURIN 2 YLAMINE; 6 CHLORO 9 (3,5 DIMETHYL 4 NITROPYRIDIN 2 YLMETHYL) 9H PURIN 2 YLAMINE; 6 CHLORO 9 (4 BROMO 3,5 DIMETHYLPYRIDIN 2 YLMETHYL) 9H PURIN 2 YLAMINE; 6 CHLORO 9 (4 CHLORO 3,5 DIMETHYLPYRIDIN 2 YLMETHYL) 9H PURIN 2 YLAMINE; 6 CHLORO 9 (4 ETHOXY 3,5 DIMETHYLPYRIDIN 2 YLMETHYL) 9H PURIN 2 YLAMINE; 6 CHLORO 9 (4 IODO 3,5 DIMETHYLPYRIDIN 2 YLMETHYL) 9H PURIN 2 YLAMINE; 6 CHLORO 9 (4 ISOPROPOXY 3,5 DIMETHYLPYRIDIN 2 YLMETHYL) 9H PURIN 2 YLAMINE; 6 CHLORO 9 (4 METHOXY 3,5 DIMETHYL N OXYPYRIDIN 2 YLMETHYL) 9H PURIN 2 YLAMINE; 6 CHLORO 9 (4 METHOXY 3,5 DIMETHYLPYRIDIN 2 YLMETHYL) 9H PURIN 2 YLAMINE; 6 CHLORO 9 (5 METHOXY 4,6 DIMETHYLPYRIDIN 3 YLMETHYL) 9H PURIN 2 YLAMINE; 6 CHLORO 9 (6 CHLORO 4 METHOXY 3,5 DIMETHYLPYRIDIN 2 YLMETHYL) 9H PURIN 2 YLAMINE; 6 MERCAPTO 9 (2 BROMO 3,4,5 TRIMETHOXYBENZYL) 9H PURIN 2 YLAMINE; 6 METHOXY 9 (2 BROMO 3,4,5 TRIMETHOXYBENZYL) 9H PURIN 2 YLAMINE; 6 METHYL 9 (2 CHLORO 3,4,5 TRIMETHOXYBENZYL) 9H PURIN 2 YLAMINE; 9 (2 BROMO 3,4,5 TRIMETHOXYBENZYL) 9H PURIN 2 YLAMINE; 9 (2 BROMO 3,4,5 TRIMETHOXYBENZYL) 9H PURINE 2,6 DIAMINE; HEAT SHOCK PROTEIN 90 INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL VIABILITY; CONTROLLED STUDY; DRUG BINDING; DRUG SOLUBILITY; DRUG STRUCTURE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

ADENINE; ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CELL LINE, TUMOR; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; PURINES; PYRIDINES; RECEPTOR, ERBB-2; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPLANTATION, HETEROLOGOUS;

EID: 34250877881     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050752+     Document Type: Article

References (67)

1. (a) Kamal, A.; Boehm, M. F.; Burrows, F. J. Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol. Med. 2004, 10, 283-290.
2. (b) Dymock, B. W.; Drysdale, M. J.; McDonald, E.; Workman, P. Inhibitors of Hsp90 and other chaperones for the treatment of cancer. Expert Opin. Ther. Patents 2004, 14, 837-847.
3. (c) Bagatell, R.; Whitesell, L. Altered Hsp90 function in cancer: A unique therapeutic opportunity. Mol. Cancer Ther. 2004, 3, 1021-1030.
4. (d) Workman, P. Trends in Isaacs, J. S.; Wanping, X.; Neckers, L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003, 3, 213.
5. (e) Maloney, A.; Workman, P. Hsp90 as a new therapeutic target for cancer therapy: The story unfolds. Expert Opin. Biol. Ther. 2002, 2, 3-24
6. (f) Richter, K.; Buchner, J. Hsp90: Chaperoning signal transduction. J. Cell. Physiol. 2001, 188, 281-290.
7. (a) Xu, W.; Mimnaugh, E.; Rosser, M. F.; Nicchitta, C.; Marcu, M.; Yarden, Y.; Neckers, L. Sensitivity of mature ErbB2 to geldanamycin is conferred by its kinase domain and is mediated by the charperone protein Hsp90. J. Biol. Chem. 2001, 276, 3702-3708.
8. (b) Schulte, T. W.; Blagosklonny, M. V.; Romanova, L.; Mushinsky, J. F.; Monia, B. P.; Johnston, J. F.; Nguyen. P.; Trepel, J.; Neckers, L. M. Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-Mitogen-Activated protein kinase signalling pathway. Mol. Cell Biol. 1996, 16, 5839-5845.
9. (c) Sato, S.; Fujita, N.; Tsuruo, T. Modulation of AKT kinase activity by binding to Hsp90. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 10832-10837.
10. (d) Stepanova, L.; Leng, X.; Parker, S. B.; Harper, J. W. Mammalian p50cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes cdk4. Genes Dev. 1996, 10, 1491-1502.
11. (e) Nimmanapalli, R.; O'Bryan, E.; Bhalla, K. Geldanamycin and its analogue 17-allylamino-17-demethoxygedanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res. 2001, 61, 1799-1804.
12. (f) Whitesell, L.; Sutphin, P. D.; Pulcini, E. J.; Martinez, J. D.; Cook, P. H. The physical association of multiple chaperone proteins with mutant p53 is altered by geldanamycin, an Hsp90-binding agent. Mol. Cell Biol. 1998, 18, 1517-1524.
13. (g) Yao, Q.; Nishiuchi, R.; Li, Q.; Kumar, A. R.; Hudson, W. A.; Kersey, J. H. FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases. Clin. Cancer Res. 2003, 9 (12), 4483-4493.
14. (a) Zhang, H.; Burrows, F. Targeting multiple signal transduction pathways through inhibition of Hsp90. J. Mol. Med. 2004, 82, 488-499.
15. (b) Workman, P. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett. 2004, 206, 149-157.
16. (c) Vilenchik, M.; Solit, D.; Basso, A.; Huezo, H.; Lucas, B.; He, H. Rosen, N.; Spampinato, C.; Modrich, P.; Chiosis, G. Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90. Chem Biol. 2004, 11, 787-797.
17. Kamal, A.; Thao, L.; Sensintaffar, J.; Zhang, L.; Boehm, M. F.; Fritz, L. C.; Burrows, F. J. A high-affinity conformation of Hsp90 confers tumor selectivity on Hsp90 inhibitors. Nature 2003, 425, 407-410.
18. (a) Pearl, L. H.; Prodromou, C. Structure, function, and mechanism of the Hsp90 molecular chaperone. Adv. Protein Chem. 2001, 59, 157-186.
19. (b) Prodromou, C.; Pearl, L. H. Structure and functional relationship of the Hsp90. Current Cancer Drug Targets 2003, 3, 301-323.
20. (a) Grenert, J. P.; Sullivan, W. P.; Fadden, P.; Haystead, T. A.; Clark, J.; Mimnaugh, E.; Krutzsch, H.; Ochel, H. J.; Schulte, T. W.; Sausville, E.; Neckers, L. M.; Toft, D. O. The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ ADP switch domain that regulates hsp90 conformation. J. Biol. Chem. 1997, 272, 23843-23850.
21. (b) Grenert, J. P.; Johnson, B. D.; Toft, D. O. The importance of ATP binding and hydrolysis by hsp90 in formation and function of protein heterocomplexes. Biol. Chem. 1999, 274, 17525-17533.
22. Lotz, G. P.; Lin, H.; Harst, A.; Obermann, W. M. Aha1 binds to the middle domain of Hsp90, contributes to client protein activation, and stimulates the ATPase activity of the molecular chaperone. J. Biol. Chem. 2003, 278, 17228-17235.
23. Marcu, M. G.; Chadli, A.; Bouhouche, I.; Catelli, M.; Neckers, L. M. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J. Biol. Chem. 2000, 275, 37181-37186.
24. (a) Panaretou, B.; Siligardi, G.; Meyer, P.; Maloney, A.; Sullivan, J. K.; Singh, S.; Millson, S. H.; Clarke, P. A.; Naaby-Hansen, S.; Stein, R.; Cramer, R.; Mollapour M, Workman, P.; Piper, P. W.; Pearl, L. H.; Prodromou, C. Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1. Mol. Cell. 2002, 10, 1307-1318.
25. (b) Workman, P. Altered states: Selectively drugging the Hsp90 cancer chaperone. Trends Mol. Med. 2004, 10, 47-51.
26. (c) Siligardi, G.; Panaretou, B.; Meyer, P.; Singh, S.; Woolfson, D. N.; Piper, P. W.; Pearl, L. H.; Prodromou, C. Regulation of Hsp90 ATPase activity by the co-chaperone Cdc37p/p50cdc37. J. Biol. Chem. 2002, 277 (23), 20151-20159.
27. (a) Le Brazidec, J.-Y.; Kamal, A.; Busch, D.; Thao, L.; Zhang, L.; Timony, G.; Grecko, R.; Trent, K.; Lough, R.; Salazar, T.; Khan, S.; Burrows, F.; Boehm, M. F. Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90. J. Med. Chem. 2004, 47, 3865-3873.
28. (b) Neckers, L.; Neckers, K. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics - An update. Expert Opin. Emerg. Drugs 2005, 10, 137-149.
29. (c) Miyata, Y. Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents. Curr. Pharm. Des. 2005, 11, 1131-1138.
30. (d) Ikuina, Y.; Amishiro, N.; Miyata, M.; Narumi, H.; Ogawa, H.; Akiyama, T.; Shiotsu, Y.; Akinaga, S.; Murakata, C. Synthesis and antitumor activity of novel O-carbamoylmethyloxime derivatives of radicicol. J. Med. Chem. 2003, 46, 2534-2541.
31. (e) Workman, P. Overview: Translating Hsp90 biology into Hsp90 drugs. Curr. Cancer Drug Targets 2003, 3, 297-300.
32. Grem, J. L.; Morrison, G.; Guo, X. D.; Agnew, E.; Takimoto, C. H.; Thomas, R.; Szabo, E.; Grochow, L.; Grollman, F.; Hamilton, J. M.; Neckers, L.; Wilson, R. H. Phase I and pharmacologic study of 17-(allylamino)-17- demethoxygeldanamycin in adult patients with solid tumors. J. Clin. Oncol. 2005, 23, 1885-1893.
33. (a) Glaze, E. R.; Smith, A. C.; Johnson, D. W.; McCormick, D. L.; Brown, A. B.; Levin, B. S.; Krishnaraj, R.; Lyubimov, A.; Egorin, M. J.; Tomaszewski, J. E. Dose range-finding toxicity studies of 17-DMAG. Proc. Am. Assoc. Cancer. Res. 2003, 44, 162-162.
34. (b) Eiseman, J. L.; Lan, J.; Lagatutta, T. F.; Hamburger, D. R.; Joseph, E.; Covey, J. M.; Egorin, M. J. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in CB-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts. Cancer Chemother. Pharmacol. 2005, 55, 21-32.
35. (a) Kasibhatla, S. R.; Hong, K.; Zhang, L.; Biamonte, M. A.; Boehm, M. F.; Shi, J.; Fan, J. Purine analogs having Hsp90 inhibiting activity. International Publication Number WO 03/037860, 2003.
36. (b) Kasibhatla, S. R.; Hong, K.; Zhang, L.; Biamonte, M. A.; Boehm, M. F.; Shi, J.; Fan, J. Purine analogs having Hsp90 inhibiting activity. US Patent Publication Number US 05/0049263, 2005.
37. (c) Kasibhatla, S. R.; Boehm, M. F.; Hong, K.; Biamonte, M. A.; Shi, J.; Le Brazidec, J. Y.; Zhang, L.; Hurst, D. Novel heterocyclic compounds as Hsp90-inhibitors. International Publication Number WO 05/028434, 2005.
38. (d) Kasibhatla, S. R.; Hong, K.; Boehm, M. F.; Biamonte, M. A.; Zhang, L. 2-Aminopurine analogs having Hsp90-inhibiting activity. US Patent Publication Number US 7,138,401, 2006.
39. (e) Kasibhatla, S. R.; Biamonte, M. A.; Shi, J.; Le Brazidec, J. Y.; Hong, K.; Boehm, M. F. Pyrrolopyrimidines and related analogs as Hsp90-inhibitors. US Patent Publication Number US 7,138,402, 2006.
40. (f) Kasibhatla, S. R.; Hong, K.; Boehm, M. F. Triazolopyrimidines and related analogs as Hsp90-inhibitors. US Patent Publication Number US 7,129,244, 2006.
41. (g) Chiosis, G.; Rosen, N. Small molecule composition for binding to hsp90. International Publication Number WO 02/ 0236075, 2002.
42. (h) Drysdale, M. J.; Dymock, B. W.; Barril-Alonso, X.; Workman, P. 3,4-Diarylpyrazoles and their use in the therapy of cancer. International Publication Number WO 03/055860, 2003.
43. (i) Chiosis, G.; Lucas, B.; Huezo, H.; Solit, D.; Basso, A.; Rosen, N. Development of purine-scaffold small molecule inhibitors of Hsp90. Curr. Cancer Drug Targets 2003, 3, 371-376.
44. (j) Llauger, L.; He, H.; Kim, J.; Aguirre, J.; Rosen, N.; Peters, U.; Davies, P. Chiosis, G. Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90. J. Med. Chem. 2005, 48, 2892-2905.
45. (k) Wright, L.; Barril, X.; Dymock, B.; Sheridan, L.; Surgenor, A.; Beswick, M.; Drysdale, M.; Collier, A.; Massey, A.; Davies, N.; Fink, a.; Fromont, C.; Aherne, W.; Boxall, K.; Sharp, S.; Workman, P.; Hubbard, R. Structure-activity relationships in purine-based inhibitor binding to Hsp90 isoforms. Chem. Biol. 2004, 11, 775-785.
46. (l) Dymock, B.; Barril, X.; Beswick, M.; Collier, A.; Davies, N.; Drysdale, M.; Fink, A.; Fromont, C.; Hubbard, R. E.; Massey, A.; Surgenor, A.; Wright, L. Adenine derived inhibitors of the molecular chaperone HSP90 - SAR explained through multiple X-ray structures. Bioorg. Med. Chem. Lett. 2004, 14, 325-328.
47. (m) Chiosis, G.; Lucas, B.; Shtil, A.; Huezo, H.; Rosen, N. Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of HER-2 tyrosine kinase. Bioorg. Med. Chem. 2002, 10, 3555-3564.
48. (n) Vilenchik, M.; Solit, D.; Basso, A.; Huezo, H.; Lucas, B.; He, H.; Rosen, N.; Spampinato, C.; Modrich, P.; Chiosis, G. Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90. Chem. Biol. 2004, 11, 787-797.
49. (o) Dymock, B. W.; Barril, X.; Brough, P. A.; Cansfield, J. E.; Massey, A.; McDonald, E.; Hubbard, R. E.; Surgenor, A.; Roughley, S. D.; Webb, P.; Workman, P.; Wright, L.; Drysdale, M. J. Novel, potent small-molecule inhibitors of the molecular charperone Hsp90 discovered through structure-based design. J. Med. Chem. 2005, 48, 4212-4215.
50. (p) Biamonte, M. A.; Shi, J.; Hong, K.; Hurst, D.; Zhang, L.; Fan, J.; Busch, D. J.; Karjian, P. L.; Maldonado, A. A.; Sensintaffar, J. L.; Kamal, A.; Lough, R. E.; Lundgren, K.; Burrows, F. J.; Timony, G. A.; Boehm, M. F.; Kasibhatla, S. R. Orally active purine-based inhibitors of Hsp90. J. Med. Chem. 2006, 49, 817-828.
51. (q) Chiosis, G.; Timaul, M. N.; Lucas, B.; Munster, P. N.; Zheng, F. F.; Sepp-Lorenzino, L.; Rosen, N. A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem. Biol. 2001, 8, 289-299.
52. (r) He, H.; Zatorska, D.; Kim, J.; Aguirre, J.; Llauger, L.; She, Y.; Wu, N.; Immormino, R. M.; Gewirth, D. T.; Chiosis, G. Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90. J. Med. Chem. 2006, 49, 381-390.
53. (a) Dymock, B.; Barril, X.; Beswick, M.; Collier, A.; Davies, N.; Drysdale, M.; Fink, A.; Fromont, C.; Hubbard, R. E.; Massey, A.; Surgenor, A.; Wright, L. Adenine derived inhibitors of the molecular chaperone HSP90 - SAR explained through multiple X-ray structures. Bioorg. Med. Chem. Lett. 2004, 14, 325-328. Structure of Hsp90 in complex with PU3 (pdb code 1UY6) and with PU24FCl (pdb code 1UYF).
54. (b) Stebbins, C. E.; Russo, A. A.; Schneider, C.; Rosen, N.; Haiti, F. U.; Pavletich, N. P. Crystal structure of an Hsp90-geldanamycin complex: Targeting of a protein chaperone by an antitumor agent. Cell 1997, 89, 239-250.
55. (c) Roe, S. M.; Prodromou, C.; O'Brien, R.; Ladbury, J. E.; Piper, P. W.; Pearl, L. H. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J. Med. Chem. 1999, 42, 260-266.
56. Tarbit, B. Preparation of pyridine derivatives. WO 99/10326.
57. Korytnyk, W.; Srivastava, S. C.; Angelino, N.; Potti, P. G. G.; Paul, B. J. Med. Chem. 1973, 16, 1096.
58. Pocker, E. J. Org. Chem. 1973, 38, 4295.
59. Holý, A.; Günter, J.; Dvoráková, H.; Masojídková, M.; Andrei, G.; Snoeck, R.; Balzarini, J.; Clercq, E. D. Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy)ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base. J. Med. Chem. 1999, 42, 2064-2086.
60. (a) Taborsky, R. G. J. Org. Chem. 1961, 26, 596.
61. (b) Yakovleva, N. L.; Balyakina, M. V.; Gunar, V. I. Khim.-Farm. Zh. 1979, 13, 85.
62. Barnes, J. H.; Hartley, F. R.; Jones, C. E. L. The preparation of 4-and 6-chloro-2-chloromethylpyridine. Tetrahedron 1982, 38, 3277-3280.
63. Sledge, G. W. HERe-2 stay: The continuing importance of translational research in breast cancer. J. Natl. Cancer Inst. 2004, 96, 725-727.
64. PWD is a dispersion of 5% Phospholipon in water. Phospholipon is a purified, soy-derived L-α-phosphatidylcholine.
65. Biamonte, M. A.; Shi, J.; Hurst, D.; Hong, K.; Boehm, M. F.; Kasibhatla, S. R. Preparation of 8-(arylsulfanyl)adenines with diazonium salts under mild, aerobic conditions. J. Org. Chem. 2005, 70, 717-720.
66. Lundgren, K.; Lough, L.; Huser, N.; Brekken, J.; Kamal, A.; Yang, C.; Zhang, H.; Timony, G.; Hong, K.; Kasibhatla, S.; Boehm, M.; Burrows, F. Manuscript in preparation.
67. Timony, G.; Grecko, R.; Khan, S.; Mansfield, R.; Ulm, E. Unpublished results.